Amcenestrant

Roche's oral selective estrogen receptor degrader (SERD) giredestrant failed to meet its primary endpoint in the phase 2 acelERA trial for advanced breast cancer. The trial results add to growing concerns about the oral SERD drug class, following similar setbacks in the field, though data suggested potential benefits in patients with higher estrogen receptor activity.

Sanofi discontinues the development of amcenestrant, an oral selective estrogen receptor degrader (SERD), after it failed in the AMEERA-5 phase 3 trial.

Arvinas plans to initiate two Phase 3 trials in 2025 for vepdegestrant in ER+/HER2- metastatic breast cancer, one in the first-line setting with atirmociclib and another in the second-line setting with a CDK4/6 inhibitor.

Imlunestrant monotherapy significantly improved progression-free survival (PFS) in advanced breast cancer patients with ESR1 mutations compared to standard endocrine therapy.

The ADELA trial investigates elacestrant combined with everolimus for ER+/HER2- advanced breast cancer with ESR1 mutations, addressing endocrine therapy resistance.